Objective: To probe into the clinical efficacy and safety of voriconazole in the treatment of invasive pulmonary fungal infections (IPFI) in children. Methods: Totally 88 children with IPFI admitted into our hospital from Feb. 2018 to Jan. 2019 were extracted to be divided into the voriconazole group and the micafungin group via the random number table

with 44 cases in each group

voriconazole and micafungin were retrospectively given for treatment of 4 to 6 weeks. Clinical efficacy and incidence of adverse drug reactions were compared between two groups. Results: The total effective rate of the voriconazole group was 93.18%

higher than 77.27% of the control group. The disappearance time of clinical symptoms

the conversion time of sputum culture

and the absorption time of imaging lesions in the voriconazole group were shorter than those in the micafungin group (P<0.05). There was no significant difference in the incidence of adverse drug reactions between two groups (P>0.05). Conclusion: The clinical efficacy of voriconazole in the treatment of children with IPFI is better than that of micafungin

and it is safe to be used as the effective anti-fungal drug for children with IPFI in clinical application.